Suppr超能文献

类风湿关节炎患者在使用托珠单抗和 csDMARDs 治疗时的生殖状态和外源性性激素使用情况。

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs.

机构信息

Health and Biomedical Innovation, UniSA: Clinical and Health Sciences, University of South Australia, Adelaide.

Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.

出版信息

Rheumatology (Oxford). 2023 Feb 1;62(2):583-595. doi: 10.1093/rheumatology/keac357.

Abstract

OBJECTIVES

Sex is well known to influence risk, severity and treatment outcomes of RA, although the underlying causes are uncertain. The aim of this research was to examine whether factors influencing female sex hormones (reproductive status and exogenous sex hormone use) are associated with the efficacy of DMARDs.

METHODS

Individual participant data were pooled from five phase 3 clinical trials where RA patients were treated with tocilizumab and/or conventional synthetic DMARDs. The primary outcome was the time to first remission according to the Simplified Disease Activity Index. The relationship between menopausal status or use of exogenous sex hormones and the time of first remission was assessed via Cox proportional analysis. Analysed data included sex, baseline menopausal status (premenopausal, perimenopausal, early postmenopausal and postmenopausal), participant age, body mass index, race, number of previous DMARDs and baseline disease activity.

RESULTS

Analysis included 4474 female patients, of whom 2817 (62.9%) were postmenopausal, 202 (4.5%) were early postmenopausal, 1021 (22.8%) were premenopausal and 414 (9.2%) were perimenopausal. Of these, 221 (7.8%), 13 (6.4%), 255 (25%) and 47 (11.4%), respectively, were taking exogenous sex hormones. In the pooled analysis, perimenopausal status was associated with reduced remission compared with premenopausal status [adjusted HR 0.78 (95% CI 0.61, 0.99)]. Sex hormone use was associated with significantly higher remission [adjusted HR 1.20 (95% CI 1.01, 1.43)].

CONCLUSION

Perimenopausal women were less likely to achieve remission compared with premenopausal RA patients. The use of exogenous sex hormones appeared to be associated with more frequent remission in female RA patients, particularly those who were perimenopausal and early postmenopausal, although further research is required to confirm and identify the drivers for this observation and how it interacts with menopausal status.

摘要

目的

性别已知会影响 RA 的风险、严重程度和治疗结果,尽管其潜在原因尚不确定。本研究旨在探讨影响女性性激素(生殖状态和外源性性激素使用)的因素是否与 DMARDs 的疗效相关。

方法

从五项 3 期临床试验中汇集了个体参与者数据,这些试验中 RA 患者接受托珠单抗和/或传统合成 DMARD 治疗。主要结局是根据简化疾病活动指数达到首次缓解的时间。通过 Cox 比例分析评估绝经状态或外源性性激素使用与首次缓解时间之间的关系。分析数据包括性别、基线绝经状态(绝经前、围绝经期、早期绝经后和绝经后)、参与者年龄、体重指数、种族、既往 DMARD 数量和基线疾病活动度。

结果

分析纳入了 4474 名女性患者,其中 2817 名(62.9%)为绝经后,202 名(4.5%)为早期绝经后,1021 名(22.8%)为绝经前,414 名(9.2%)为围绝经期。其中,分别有 221 名(7.8%)、13 名(6.4%)、255 名(25%)和 47 名(11.4%)正在服用外源性性激素。在汇总分析中,与绝经前状态相比,围绝经期状态与缓解率降低相关[调整后的 HR 0.78(95%CI 0.61,0.99)]。性激素的使用与更高的缓解率显著相关[调整后的 HR 1.20(95%CI 1.01,1.43)]。

结论

与绝经前 RA 患者相比,围绝经期女性更不易达到缓解。外源性性激素的使用似乎与女性 RA 患者更频繁的缓解相关,尤其是围绝经期和早期绝经后患者,但需要进一步研究来证实和确定这一观察结果的驱动因素以及它与绝经状态的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab54/9891436/e8de68204da7/keac357f5.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验